NCT05412680

Brief Summary

Prospective study carried out with ICESP (instituto do Câncer do Estado de São Paulo) patients with thyroid disease with surgical indication

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started May 2022

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 18, 2022

Completed
7 days until next milestone

Study Start

First participant enrolled

May 25, 2022

Completed
15 days until next milestone

First Posted

Study publicly available on registry

June 9, 2022

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2024

Completed
Last Updated

May 14, 2024

Status Verified

March 1, 2024

Enrollment Period

2.6 years

First QC Date

May 18, 2022

Last Update Submit

May 12, 2024

Conditions

Outcome Measures

Primary Outcomes (8)

  • To compare TOETVA technique with conventional thyroidectomy in terms of operative time

    Operative time will be measured by minutes

    1 year

  • To compare TOETVA technique with conventional thyroidectomy in terms of post operative surgical complications, such as laryngeal nerve dysfunction

    This outcome will be accessed by performing laryngoscopy before and after the surgery

    1 year

  • To compare TOETVA technique with conventional thyroidectomy in terms of post operative surgical complications, such as hypoparathyroidism

    This outcome will be accessed by accessing de blood calcium and parathormone levels after the surgery

    1 year

  • To compare TOETVA technique with conventional thyroidectomy in terms of post operative surgical complications, such as hematoma formation

    This outcome will be accessed by qualitative analysis

    1 year

  • To compare TOETVA technique with conventional thyroidectomy in terms of post operative surgical complications, such as seroma formation

    This outcome will be accessed by qualitative analysis

    1 year

  • To compare TOETVA technique with conventional thyroidectomy in terms of post operative surgical complications, such as skin injury

    This outcome will be accessed by qualitative analysis

    1 year

  • To compare TOETVA technique with conventional thyroidectomy in terms of post operative pain

    This outcome will be accessed by visual pain scale from grade 1 (better) to 10 (worse)

    1 year

  • To compare TOETVA technique with conventional thyroidectomy in terms of time of hospitalization

    This outcome will be accessed by number of days spent in the hospital

    1 year

Secondary Outcomes (3)

  • Comparison on quality of life - questionnaire 1.

    1 year

  • Comparison on quality of life - questionnaire 2.

    1 year

  • Comparison on quality of life - questionnaire 3.

    1 year

Study Arms (2)

TOETVA

ACTIVE COMPARATOR

Patients submitted to transoral endoscopic thyroidectomy by vestibular approach

Procedure: TOETVA

CONVENTIONAL THYROIDECTOMY

ACTIVE COMPARATOR

Patients submitted to conventional open thyroidectomy by cervical approach

Procedure: conventional thyroidectomy

Interventions

TOETVAPROCEDURE

TRANSORAL ENDOSCOPIC THYROIDECTOMY BY VESTIBULAR APPROACH

TOETVA

conventional open thyroidectomy by cervical approach

CONVENTIONAL THYROIDECTOMY

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • history of hypertrophic scarring and/or motivation to avoid cervical scarring,
  • maximum diameter of the thyroid \< 10 cm and of the dominant nodule \< 6 cm,
  • estimated thyroid volume \< 45 ml
  • benign lesion (multinodular goiter, cyst),
  • indeterminate nodule (Bethesda III or IV),
  • suspicious nodule for well-differentiated thyroid carcinoma (Bethesda V and VI) \< 2 cm

You may not qualify if:

  • history of previous surgery or irradiation in the head and neck region and superior mediastinum
  • evidence of clinical hyperthyroidism
  • preoperative recurrent nerve palsy
  • lymph node metastasis
  • extra-thyroid extension
  • plunging goiter
  • oral abscess

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

ICESP

São Paulo, São Paulo, 01246000, Brazil

RECRUITING

MeSH Terms

Conditions

Thyroid DiseasesThyroid Neoplasms

Condition Hierarchy (Ancestors)

Endocrine System DiseasesEndocrine Gland NeoplasmsNeoplasms by SiteNeoplasmsHead and Neck Neoplasms

Study Officials

  • Fabio Capelli, phd

    Instituto do Cancer do Estado de São Paulo

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

May 18, 2022

First Posted

June 9, 2022

Study Start

May 25, 2022

Primary Completion

December 31, 2024

Study Completion

December 31, 2024

Last Updated

May 14, 2024

Record last verified: 2024-03

Locations